Legacinetics is commercialising dual-platform iPSC-derived iMSC exosome technology to deliver transformative therapies for Alzheimer’s, neuroinflammation, and metabolic diseases. A novel, patent-protected iPSC-derived, gene-edited MSC-exosome platform —engineered to increase allogenicity, cross the blood-brain barrier and address the metabolic roots of neurodegeneration and other related indications.
A gene-edited, iPSC-derived exosome platform built on Nobel Prize–winning science — engineered to cross the blood–brain barrier and target the roots of neurodegeneration.
Guided by the people who built the field — led by co-founders with direct ties to Nobel Laureate Prof. Shinya Yamanaka, and backed by an advisory committee from Harvard, Monash and the Roslin Institute
At Legacinetics, we are building a platform with the potential to redefine how Alzheimer's and related metabolic diseases are treated. We welcome the opportunity to speak with investors who share our commitment to scientific rigor and long-term value creation — leave your details below and our investor relations team will follow up directly.
